Allergan, Inc.

Terrence J. Hunt

Terrence J Hunt

Patrick Michael Hughes

Peter G Bakhit

James Nienyuan Chang

Michael R Robinson

Scott M Whitcup

Wendy M Blanda

Roger Kei Aoki

David C Rupp

Ester Fernandez-Salas

Joseph Francis

Eric A Forssen

Jack Z Xie

Ron S Broide

Michael B Shah

Harish P Kumar

Gary Shimizu

Huong T Tran

Harish Pm Kumar

Ananda Seneviratne

Alex Praseuth

Gopal Dasari

Don Mathewson

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

Animal protein-free pharmaceutical compositions

Method for stabilizing a toxin

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.

Sustained release poloxamer containing pharmaceutical compositions

Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.

Formulations of biologics for intravesical instillation

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.

Botulinum toxin compositions

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

Pharmaceutical compositions containing botulinum toxin

neurotoxin formulated with a hyaluronic acid carrier with increased residency time of thetoxin at a subdermal location and fewertoxin induced complications or side effects.

[object Object]

Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.

Botulinum toxin formulation

A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol.

Non-protein stabilized Clostridial toxin pharmaceutical compositions

A botulinum toxin pharmaceutical formulation comprising a botulinum toxin and a low molecular weight recombinant or native gelatin fragment suitable for administration to a human patient, and methods for treating patients with various diseases and afflictions using the formulation.

Growing community of inventors

Corona, CA, United States of America

Terrence J Hunt